Compare RLX Technology Inc (RLX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
RLX Technology Inc vs Recursion Pharmaceuticals Inc — how do they compare? RLX Technology Inc trades at $1.98 (market cap $2.44B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B). The key difference: RLX Technology Inc is the larger of the two by market cap, and RLX Technology Inc pays a 5% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RLX | RXRX | |
|---|---|---|
Market Cap | $2.44B | $1.78B |
Sector | Technology | Health |
52-Week High | $2.73 | $6.79 |
52-Week Low | $1.79 | $2.84 |
Enterprise Value | $1.07B | $1.30B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RLX Technology trades at $2.01, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth to $4.4B with a net profit margin of 22.47%, though it missed EPS estimates for three consecutive quarters. Recent news highlights international expansion, including European integration and a 70% international revenue share.
Outlook is mixed: strong fundamentals with cash flow from operations and no debt support growth, but earnings misses and regulatory risks in the vaping industry pose challenges. The sole analyst coverage recommends Hold, reflecting cautious optimism amid execution risks.
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
